# A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

> **NCT00755287** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1072 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** insulin glargine
- **DRUG:** metformin
- **DRUG:** taspoglutide
- **DRUG:** taspoglutide

## Key facts

- **NCT ID:** NCT00755287
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 1072 (ACTUAL)
- **Last updated:** 2016-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755287, "A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00755287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*